Business
PTC THERAPEUTICS, INC.: We are advancing a robust and diversified pipeline of transformative medicines as PART of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
Revenue increased 114.5% to $1.73B, while Net income increased 287.9% to $682.6M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $1.73BOK
- Profitability — Net income $682.6MOK
- Cash generation — Free cash flow $702.3MOK
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 70 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as PTC THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Collaboration And License Revenue$1.0B
- Product$586.7M
- Royalty$244.2M
- Translarna1$235.3M
- Emflaza$146.4M
Leadership changes
From PTC THERAPEUTICS, INC.'s own filings, the day they're filed.
- Alethia Young · member of the board of directors · departureeff. 2026-06-08
- Jessica Chutter · directors · appointmenteff. 2026-03-24
- Emily Hill · Chief Financial Officer · departureeff. 2023-08-20
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about PTC THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.